COVID-19 vaccines: where did we stand at the end of 2023?

K Lundstrom - Viruses, 2024‏ - mdpi.com
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

NA Kaabi, YK Yang, J Zhang, K Xu, Y Liang… - … and Targeted Therapy, 2022‏ - nature.com
The increased coronavirus disease 2019 (COVID-19) breakthrough cases pose the need of
booster vaccination. We conducted a randomised, double-blinded, controlled, phase 2 trial …

Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort …

X Chen, H Wang, J Ai, L Shen, K Lin… - Emerging Microbes & …, 2022‏ - Taylor & Francis
To further describe the effect of the “fragile population” and their “higher-risk” comorbidities
on prognosis among hospitalized Omicron patients, this observational cohort study enrolled …

COVID-19 Vaccines—All You Want to Know

AA Shishido, AH Barnes, S Narayanan… - … in Respiratory and …, 2023‏ - thieme-connect.com
The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic has led to
an unprecedented public health crisis. The collective global response has led to production …

Spontaneous intramedullary hematoma following COVID‐19 vaccination: A case report

A Sourani, M Rezvani, M Foroughi… - Clinical Case …, 2022‏ - Wiley Online Library
A 67‐year‐old female was hospitalized due to right‐sided hemiparesis and neck pain with
rapid deterioration to a deep coma. She had received the Sinopharm vaccine 2 days earlier …

[HTML][HTML] Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine

C Lu, Y Zhang, X Liu, F Hou, R Cai, Z Yu, F Liu… - Antiviral Research, 2023‏ - Elsevier
The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage.
This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron …

Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines

A Hromić-Jahjefendić, K Lundstrom, M Adilović… - Autoimmunity …, 2024‏ - Elsevier
The complicated relationships between autoimmunity, COVID-19, and COVID-19
vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA) …

The Assessment of Anti–SARS‐CoV‐2 Antibodies in Different Vaccine Platforms: A Systematic Review and Meta‐Analysis of COVID‐19 Vaccine Clinical Trial Studies

M Mirzakhani, M Bayat, M Dashti… - Reviews in Medical …, 2024‏ - Wiley Online Library
ABSTRACT Background and Objective The COVID‐19 pandemic spread rapidly throughout
the world and caused millions of deaths globally. Several vaccines have been developed to …

Construction and validation of a risk model of proteinuria in patients with omicron COVID‐19: retrospective cohort study

L Teng, G Chang, X Song, M Zhang, Y Han… - Renal …, 2024‏ - Taylor & Francis
Background To explore the risk factors of proteinuria in Omicron variant patients and to
construct and verify the risk predictive model. Methods 1091 Omicron patients who were …